Everything below concerns prothymosin alpha. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-12. Numbers and descriptions here follow the published literature rather than marketing material.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
| Property | Value | Notes |
|---|---|---|
| Primary structure | 28 amino acid residues | N-terminally acetylated |
| Net charge at neutral pH | Negative | Acidic peptide |
| Typical purity assay | Reverse-phase HPLC | UV detection near 214 nm |
| Identity confirmation | Mass spectrometry | Matches expected molecular mass |
| Reconstitution solvent | Sterile water or saline | Follow supplier instructions |
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
in the PAMn matrix which results in the best score is most likely to correspond to the mutations per amino acid separating the two proteins. Halving this value and dividing by the rate at which accepted mutations accumulate in the protein family provides an estimate of the time of divergence of these two proteins from their common ancestor. That is, the time of divergence in myr is
Matter is composed of atoms and what makes up atoms. Matter has intrinsic or rest mass. In the limited range of recognized experience of the nineteenth century, it was found that such rest mass is conserved. Einstein's 1905 theory of special relativity showed that rest mass corresponds to an equivalent amount of rest energy. This means that rest mass can be converted to or from equivalent amounts of (non-material) forms of energy, for example, kinetic energy, potential energy, and electromagnetic radiant energy. When this happens, as recognized in twentieth-century experience, rest mass is not conserved, unlike the total mass or total energy. All forms of energy contribute to the total mass and total energy. For example, an electron and a positron each have rest mass. They can perish together, converting their combined rest energy into photons which have electromagnetic radiant energy but no rest mass. If this occurs within an isolated system that does not release the photons or their energy into the external surroundings, then neither the total mass nor the total energy of the system will change. The produced electromagnetic radiant energy contributes just as much to the inertia (and to any weight) of the system as did the rest mass of the electron and positron before their demise. Likewise, non-material forms of energy can perish into matter, which has rest mass. Thus, conservation of energy (total, including material or rest energy) and conservation of mass (total, not just rest) are one (equivalent) law.
== Discovery == Asprosin was first identified by Dr. Atul Chopra and colleagues at Baylor College of Medicine during their study of Marfanoid–progeroid–lipodystrophy syndrome (MPL), also known as neonatal progeroid syndrome (NPS), a rare genetic disorder caused by mutations in the FBN1 gene. These mutations produce truncated profibrillin-1 protein, resulting in two key effects: the production of a mutant fibrillin-1 protein and significantly reduced plasma asprosin levels due to a dominant-negative mechanism. The discovery of asprosin's role as a fasting-induced glucogenic hormone, stimulating hepatic glucose release, stemmed from the observation of low plasma insulin levels in the two patients. A subsequent study by Chopra and colleagues investigated the patients' extreme thinness and abnormally low appetite, uncovering asprosin's additional role as an orexigenic hormone that regulates appetite through hypothalamic neurons. To further investigate the condition, Chopra and colleagues developed a mouse model carrying the MPL mutation, which faithfully phenocopied the human disorder. These mice exhibited the same features as the patients, including low plasma asprosin levels, extreme thinness, reduced appetite, and resistance to diet-induced obesity and diabetes. This model confirmed the role of asprosin in regulating appetite and body weight through its orexigenic effects on hypothalamic neurons and demonstrated its broader implications in metabolic health.
Sources: en.wikipedia.org
== History == Etoperidone was discovered by scientists at Angelini, who also discovered trazodone. Its development names have included ST-1191 and McN-A-2673-11. The INNTooltip International Nonproprietary Name etoperidone was proposed in 1976 and recommended in 1977. The drug was given brand names in Spain (Centren (Esteve) and Depraser (Lepori)) and Italy (Staff (Sigma Tau)) and was also given the brand names Axiomin and Etonin, but it is not entirely clear if it was actually marketed; the Pharmaceutical Manufacturing Encyclopedia provides no dates for commercial introduction. According to Micromedex's Index Nominum: International Drug Directory, etoperidone was indeed previously marketed in Spain and Italy.
== History == The benefit and side effects of loncastuximab tesirine were evaluated in one clinical trial, ADCT-402-201 (LOTIS-2 / NCT03589469), that included 145 participants with relapsed or refractory diffuse large B-cell lymphoma after at least two prior treatments that did not work or were no longer working. Participants received loncastuximab tesirine 0.15 mg/kg every 3 weeks for 2 treatment cycles, then 0.075 mg/kg every 3 weeks for subsequent treatment cycles. Loncastuximab tesirine treatment was continued until either disease worsened or participants experienced unacceptable side effects (toxicity). The benefit of loncastuximab tesirine was evaluated by measuring how many participants had complete or partial tumor shrinkage (response) and by how long that response lasted. Participants in the clinical trial were also evaluated for side effects for the purpose of this drug application. Trials were conducted at 28 sites in the United States, the United Kingdom, Italy, and Switzerland. Loncastuximab tesirine was granted orphan drug designation by the FDA for the treatment of diffuse large B-cell lymphoma. Loncastuximab tesirine was approved under FDA's accelerated approval program.
Canned (tinned) instant soups contain liquid soup that is prepared by heating their contents. Some canned soups are condensed, and require additional water to bring them to their intended strength, while others are canned in a ready-to-eat, single-strength form. Dr. John T. Dorrance, an employee with the Campbell Soup Company, invented condensed soup in 1897. Consumers sometimes use condensed soups (without diluting them), as a sauce base. Some instant liquid soups are manufactured in microwaveable containers. Additionally, some instant soups, such as Knorr's Erbswurst, are prepared in a concentrated paste form. Knorr ceased production of Erbswurst on December 31, 2018. Instant noodle soups such as Cup Noodles contain dried instant ramen noodles, dehydrated vegetable and meat products, and seasonings, and are prepared by adding hot water. Packaged instant ramen noodle soup is typically formed as a cake, and often includes a seasoning packet that is added to the noodles and water during preparation. Some also include separate packets of oil and garnishes used to season the product. Momofuku Ando, the founder of Nissin Foods, developed packaged ramen noodle soup in 1958.
=== Pittsburgh Pirates (1960–62) === Mizell's trade to the Pirates was one of the catalysts of Pittsburgh's championship run that season. Facing the Giants on June 16, 1960, he threw 166 pitches and stayed in the ballgame for three hours and two minutes, allowing two runs through eight innings before allowing three hits to start the ninth and getting charged with three more runs, though he still earned the win in the 10–7 victory. "Shucks, no. I wasn't tired," he quipped after the game. On the strength of two shutouts, he pitched 30 consecutive scoreless innings from July 22 to August 9, the longest such streak of his career. The first shutout may have been his best game of the season; he held the Cubs to two hits in a 4–0 victory on July 29. Six days later, he allowed five hits but no runs to the Giants, securing a 1–0 triumph. On September 18, he won another 1–0 game, limiting Cincinnati to three hits in nine innings. In the month of September, he had a 5–1 record and a 3.14 ERA as the Pirates clinched the NL pennant. Mizell went 13-5 for the Pirates that season (14–8 overall) and finished sixth in the NL in winning percentage (.636). Between St. Louis and Pittsburgh, he had a 3.50 ERA (3.12 with the Pirates), striking out 113 and walking 74 in 211 innings. Of the walks, 10 were intentional. Mizell started Game 3 of the 1960 World Series against the New York Yankees but was removed in the first inning, having given up three hits and a walk while only retiring one hitter. He was charged with the loss as the Yankees won 10–0.
Sources: en.wikipedia.org
=== Antibacterial === Recently, carbon-nanotubes have been shown to have antibacterial properties. They disrupt normal bacterial function by causing physical/mechanical damage, facilitating oxidative stress or lipid extraction, inhibiting bacterial metabolism, and isolating functional sites via wrapping with CNM-containing nanomaterials.
==== Companion of the Order of St Michael and St George (CMG) ==== Jennifer Elizabeth Anderson, Director, Consular and Crisis, Foreign, Commonwealth and Development Office. For services to British Foreign Policy and to British Nationals Overseas. Zamir Nicholas Catasaras, Director General for Russia and Ukraine, Cabinet Office. For services to British Foreign Policy. Roger James Coventry, Criminal Justice Adviser. For services to Justice and Stability overseas. Colin Mark Evans, Director General, Foreign, Commonwealth and Development Office. For services to National Security. Dr Fiona Hill, Senior Fellow, Brookings Institution, Washington D.C., United States of America. For services to International Relations. Dr Rurik Miles Marsden, , Development Director, British Embassy Yangon, Myanmar. For services to International Development. Susanna Mary Davies Moorehead, lately Chair, Development Assistance Committee, The Organisation for Economic Co-operation and Development (OECD). For services to International Development and Diplomacy. Jane Anne Nelson, Director, Corporate Responsibility Initiative, Kennedy School of Government, Harvard University, United States of America. For services to Business and to Sustainability. Dr Sara Pantuliano, Chief Executive, ODI. For services to Peacebuilding, to Humanitarian Assistance and to International Development. Simon Penny, lately H.M. Trade Commissioner for the Middle East and Pakistan and H.M. Consul General to Dubai and the Northern Emirates. For services to International Trade and Investment.
Biologic debridement has the added benefit of being bactericidal since larvae will ingest bacteria as well as devitalized tissue. Despite the safety and effectiveness of this method, its applications are often limited due to patient's negative feelings towards larvae which are commonly associated with poor hygiene and perishable food.
Sources: en.wikipedia.org
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.
Reverse-phase HPLC separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the expected molecular mass and flags sequence errors. The two techniques are commonly reported together on a certificate of analysis.
Short exposure during handling is not considered a major problem for the dry powder. Prolonged storage at ambient temperature, especially of reconstituted solutions, raises the risk of degradation. Cold storage remains the standard practice for longer periods.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.